“Genotoxicity, carcinogenicity and reproductive and developmental toxicity studies were not performed for remestemcel-L.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Carcinogenicity
Not conducted; 6-week nude mouse tumorigenicity study showed no tumors
“There was no evidence of neoplastic tissue formation attributable to ceMSC over the six-week duration of the study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not applicable: cells not genetically modified
“Genotoxicity, carcinogenicity and reproductive and developmental toxicity studies were not performed for remestemcel-L.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted (not warranted)
“Genotoxicity, carcinogenicity and reproductive and developmental toxicity studies were not performed for remestemcel-L.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Safety pharmacology
GLP rat pulmonary function study (high mortality at >=16x10^6 cells/kg) and pig cardiac study (no effects)
“A GLP safety pharmacology study evaluating pulmonary function in rats was conducted with single IV administration of rat-derived ceMSC”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Genotox: Ames
Not conducted
“No genotoxicity studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗
Genotox: in vitro mammalian
Not conducted
“No genotoxicity studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗
Genotox: in vivo
Not conducted
“No genotoxicity studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗
Carcinogenicity model
Six-week tumorigenicity study in athymic mice, human ceMSC up to 50x10^6 cells/kg: no neoplastic tissue
“In a tumorigenicity study in athymic mice, administration of human ceMSC from five separate donors was evaluated at dose levels up to 50x106 cells/kg. There was no evidence of neoplastic tissue formation attributable to ceMSC over the six-week duration of the study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Carcinogenicity timing
Not required: not warranted based on product characteristics and safety profile
“Genotoxicity, carcinogenicity, and reproductive and developmental toxicity studies were not performed for RYONCIL. These studies are not warranted based on the product characteristics and safety profile.”
✓ VerifiedFDA summary basis for approval, p. 13Source ↗
hERG / QT
Pig cardiac safety pharmacology study (single IV allogeneic pig ceMSC): no product-related effects on cardiac function
“A cardiac safety pharmacology study in pigs was conducted with single IV infusion of 1x106 and 10x106 allogeneic pig ceMSC/kg using a catheter at a constant rate of 2-3 mL/min. No product-related effects on cardiac function were observed.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗